Topical 15% resorcinol for hidradenitis suppurativa: An uncontrolled prospective trial with clinical and ultrasonographic follow-up

Pascual, José C.; Encabo, Belén; Apodaca, Rosa F. Ruiz de; Romero, David; Selva, Juan Pablo; Jemec, Gregor B. E.

doi:10.1016/j.jaad.2017.07.008

Cited by 28 publications

(29 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They also suggested that resorcinol had no influence on scarring, fibrosis or deep‐seated lesions as sinus tracts 7 . In a prospective study (32 patients), 8 Pascual et al . demonstrated the efficacy of resorcinol 15% applied twice daily for 30 days in HS lesions.…”

Section: Clinical Hs Score Week T0 T4 T12mentioning

confidence: 97%

“…It is characterized by a keratolytic effect, antimicrobial and anti‐inflammatory properties, and by modulating prostaglandin formation. The use of resorcinol in HS has been poorly described in the literature and it is usually limited in the short‐term management of HS flares 7,8 . Boer and Jemec, 7 in a small retrospective study, defined topical resorcinol 15% as a beneficial self‐administered treatment for acute flare, reducing pain and duration of manifestations.…”

Section: Clinical Hs Score Week T0 T4 T12mentioning

confidence: 99%

“…demonstrated the efficacy of resorcinol 15% applied twice daily for 30 days in HS lesions. The use of topical resorcinol was associated with a significant reduction in pain and the size of inflammatory nodules and abscesses (fistulous tracts were excluded) 8 …”

Section: Clinical Hs Score Week T0 T4 T12mentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of topical resorcinol 15% as long‐term treatment of mild‐to‐moderate hidradenitis suppurativa: a valid alternative to clindamycin in the panorama of antibiotic resistance

et al. 2020

View full text Add to dashboard Cite

until 1 week, in four patients (10%) until 2 weeks, and in two patients (5%) until 3 weeks after the patient was cured. The mean mite DNA load during these periods was only 4Á20% (95% confidence interval 0Á93-7Á47) of the peak DNA load, and none of these patients had clinical or microscopic recurrence of infestation. Therefore, scabies mite DNA may be detectable during the follow-up period after cure, but its presence may be the result of epidermal turnover to liberate mite DNA rather than relapse or treatment failure, especially if the DNA load is less than 10% of the peak load In conclusion, our study demonstrated that a nested realtime quantitative PCR assay targeting the cox1 gene of S. scabiei is useful not only for the diagnosis of scabies but also for post-treatment monitoring. This PCR assay may not completely replace traditional skin scraping and microscopic examinations in terms of time and cost, but it may help physicians who have not previously diagnosed scabies or used dermoscopy to diagnose scabies accurately. The assay may also be helpful in the diagnosis of patients with atypical symptoms and signs, and may be helpful in identifying cure or recurrence during post-treatment monitoring.

show abstract

Section: Clinical Hs Score Week T0 T4 T12mentioning

confidence: 97%

Section: Clinical Hs Score Week T0 T4 T12mentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of topical resorcinol 15% as long‐term treatment of mild‐to‐moderate hidradenitis suppurativa: a valid alternative to clindamycin in the panorama of antibiotic resistance

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The 15% resorcinol has been reported in one retrospective and one prospective study in HS. 54,55 Benefit was seen in patients with Hurley stage 1 and 2 disease, with twice daily application for 30 days with reduction in size of visible lesions, pain and erythema. The mechanism of action of resorcinol in HS is proposed to be keratolytic at the follicular infundibulum.…”

Section: Topical Therapies In Hsmentioning

confidence: 99%

Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms

Frew

Hawkes

Krueger

2019

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the skin, manifesting in chronic, recurrent painful pustules, nodules, boils and purulent draining abscesses. Our current understanding of the pathogenesis of the disease is incomplete. This review aims to identify available treatment options in HS and discuss the pharmacological mechanisms through which such agents function. Identifying common pathways may inform our understanding of the pathogenesis of HS as well as identify future therapeutic targets. The pharmacological mechanisms implicated in topical therapies, antibiotic, hormonal, systemic immunomodulatory and biologic therapies for HS are discussed. Significant differences exist between agents and implicated pathways in therapy for mild and severe disease. This is an expression of the possible dichotomy in inflammatory pathways (and treatment responses) in HS. Studies involving monoclonal antibodies provide the greatest insight into what these specific mechanisms may be. Their variable levels of clinical efficacy compared with placebo bolsters the suggestion that differential inflammatory pathways may be involved in different presentations and severity of disease. Nuclear factor kappa B (NF-κB), tumor necrosis factor (TNF)-α and other innate immune mechanisms are strongly represented in treatments which are effective in mild to moderate disease in the absence of scarring or draining fistulae, however complex feed-forward mechanisms in severe disease respond to interleukin (IL)-1 inhibition but are less likely to respond to innate immune inhibition (through NF-κB or TNF-α) alone. It is unclear whether IL-17 inhibition will parallel TNF-α or IL-1 inhibition in effect, however it is plausible that small molecule targets (Janus kinase1 and phosphodiesterase 4) may provide effective new strategies for treatment of HS.

show abstract

“…Resorcinol [C 6 H 4 (OH) 2 1,3-dihydroxybenzene] is a phenol derivate with anti-inflammatory activity that has proven efficacy in the treatment for hidradenitis suppurative. 3,4 Hyperpigmentation, skin irritation and peeling are the most frequent side effects regarding its topical use, although these are normally well tolerated by the patient.…”

mentioning

confidence: 99%

Dissecting cellulitis of the scalp successfully treated with topical resorcinol 15%

Navarro‐Triviño

Almazán-Fernández

Ródenas‐Herranz

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Dissecting cellulitis (DC), also called folliculitis abscedens or perifolliculitis capitis abscedens et suffodiens, is an inflammatory, chronic, and recurrent disease of the hair follicle. Pathophysiology of DC remains unclear, but some authors suggest an important role of the neutrophils and the inflammatory via interlekin-1. DC probably shows genetic influence, which can be triggered by environmental factors. It predominantly affects the male sex. Clinical lesions are mainly observed on the vertex and occipital region. Afro-Caribbean race patients exhibit a higher incidence of this disease. 1 DC clinically begins with papulopustular lesions which evolve to a noncicatricial alopecia, and later, multifocal nodules and abscesses,

show abstract

Topical 15% resorcinol for hidradenitis suppurativa: An uncontrolled prospective trial with clinical and ultrasonographic follow-up

Cited by 28 publications

References 2 publications

Efficacy and safety of topical resorcinol 15% as long‐term treatment of mild‐to‐moderate hidradenitis suppurativa: a valid alternative to clindamycin in the panorama of antibiotic resistance

Efficacy and safety of topical resorcinol 15% as long‐term treatment of mild‐to‐moderate hidradenitis suppurativa: a valid alternative to clindamycin in the panorama of antibiotic resistance

Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms

Dissecting cellulitis of the scalp successfully treated with topical resorcinol 15%

Contact Info

Product

Resources

About